Skyepharma to go public via a SPAC merger with eureKING.

Skyepharma, a pharmaceutical CDMO, is set to go public via a SPAC merger with eureKING, a special purpose acquisition company,. Financial terms were not disclosed. “This transaction would be a critical milestone of our ambitious project to build a leading European bio-CDMO player. In Skyepharma, we have found a partner that matches all of our investment criteria, including quality of business and assets, a clear path to growth, a scalable platform and a strong management team that has a proven track record in turnarounds and integrating manufacturing businesses. eureKING was formed with long-term investors and highly-qualified executives, committed to bringing together the most innovative European players in biomanufacturing to service the biopharmaceutical industry. By adding David and Benoit’s track record of manufacturing and operational excellence within the industry, we are ready to tackle a high-growth market and deliver sustainable value to our shareholders,” Michael Kloss, eureKING Co-Founder and CEO.